Moreover, two recent reviews summarised current and emerging therapeutic approaches to NAFLD treatment [14, 59] and highlighted the importance of novel targets, such as PPARs, Nrf2, SREBP2, and SIRT1, in the treatment of fat accumulation, inflammation, and OS. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.